@xconomy.com 6 months ago
With Bristol and Otsuka on Board, LSP Raises $620M EU Life Sciences Fund
@xconomy.com 7 months ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com 12 months ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com 1 year ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com 1 year ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 1 year ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com 1 year ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com 1 year ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com 1 year ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com 1 year ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com 1 year ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com 1 year ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com 1 year ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com 1 year ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com 1 year ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com 1 year ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com 1 year ago
Former Zavante Executive Tapped as Abide Therapeutics President
@xconomy.com 1 year ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com 1 year ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com 1 year ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com 1 year ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com 1 year ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com 1 year ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push
@xconomy.com 2 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M